“We are excited to collaborate with Scienture to enhance its commercial effectiveness,” said Paul Mignon, President, Deployment Solutions, Syneos Health. “Our team is committed to delivering tailored ...
Orion Corporation, the globally operating Finnish pharmaceutical company, has opened its Biologics R&D Centre at Babraham ...
German business-software group SAP claimed the top spot as Europe’s largest company by market value, dethroning Danish ...
The Print on MSN5d
How reciprocal Trump tariffs may impact Indian pharma, and become a bitter pill for the USSpooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...
The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology; Servier will develop and commercialize BDTX-4933, a ...
CIBC’s Krista Friesen maintained her “underperformer” rating (similar to sell) and cut her target to $15 from $17, saying in ...
Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...
Harmony Biosciences has named Adam Zaeske its next chief commercial officer, luring the Takeda veteran back from Europe to ...
Announced in December 2024, David Enloe joins as the division’s CEO. He has experience leading life science CDMOs such as ...
The demise of the pharmaceutical sales representative has been greatly exaggerated over the years. But in the wake of the COVID-19 pandemic, there is an even greater need to re-examine the rep's role.
2025 will be a challenging year for many sectors with multiple headwinds, and the pharmaceutical industry ... a pill for that… Michael Burkhard is executive industry consultant for pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback